D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $25.00 price objective on the stock.

Several other research firms have also issued reports on HUMA. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Price Performance

NASDAQ:HUMA traded down $0.86 during trading hours on Wednesday, reaching $2.03. 10,841,548 shares of the company were exchanged, compared to its average volume of 2,382,382. The business has a 50 day moving average of $3.76 and a 200 day moving average of $4.57. Humacyte has a 1-year low of $1.99 and a 1-year high of $9.97. The company has a market capitalization of $254.86 million, a P/E ratio of -1.51 and a beta of 1.36.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. acquired a new stake in shares of Humacyte in the 4th quarter valued at approximately $50,000. Petros Family Wealth LLC acquired a new stake in Humacyte in the fourth quarter valued at approximately $50,000. Syon Capital LLC acquired a new stake in Humacyte in the fourth quarter valued at approximately $54,000. Brookstone Capital Management bought a new stake in shares of Humacyte during the fourth quarter worth $56,000. Finally, ACT Wealth Management LLC acquired a new position in shares of Humacyte during the fourth quarter worth $57,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.